These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 28179134

  • 1. Inhibition of cytochrome P450 enzymes by saturated and unsaturated fatty acids in human liver microsomes, characterization of enzyme kinetics in the presence of bovine serum albumin (0.1 and 1.0% w/v) and in vitro - in vivo extrapolation of hepatic clearance.
    Palacharla RC, Uthukam V, Manoharan A, Ponnamaneni RK, Padala NP, Boggavarapu RK, Bhyrapuneni G, Ajjala DR, Nirogi R.
    Eur J Pharm Sci; 2017 Apr 01; 101():80-89. PubMed ID: 28179134
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The "albumin effect" and in vitro-in vivo extrapolation: sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9.
    Rowland A, Elliot DJ, Knights KM, Mackenzie PI, Miners JO.
    Drug Metab Dispos; 2008 May 01; 36(5):870-7. PubMed ID: 18256202
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. In vitro-in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6α-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearance.
    Wattanachai N, Polasek TM, Heath TM, Uchaipichat V, Tassaneeyakul W, Tassaneeyakul W, Miners JO.
    Eur J Clin Pharmacol; 2011 Aug 01; 67(8):815-24. PubMed ID: 21305272
    [Abstract] [Full Text] [Related]

  • 6. The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities.
    Rowland A, Knights KM, Mackenzie PI, Miners JO.
    Drug Metab Dispos; 2008 Jun 01; 36(6):1056-62. PubMed ID: 18362158
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A comprehensive assay for nine major cytochrome P450 enzymes activities with 16 probe reactions on human liver microsomes by a single LC/MS/MS run to support reliable in vitro inhibitory drug-drug interaction evaluation.
    Peng Y, Wu H, Zhang X, Zhang F, Qi H, Zhong Y, Wang Y, Sang H, Wang G, Sun J.
    Xenobiotica; 2015 Jun 01; 45(11):961-77. PubMed ID: 26007223
    [Abstract] [Full Text] [Related]

  • 9. Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, and in vitro-in vivo correlation.
    Obach RS.
    Drug Metab Dispos; 2000 Sep 01; 28(9):1069-76. PubMed ID: 10950851
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Inhibition of cytochrome P450 enzymes involved in ketamine metabolism by use of liver microsomes and specific cytochrome P450 enzymes from horses, dogs, and humans.
    Mössner LD, Schmitz A, Theurillat R, Thormann W, Mevissen M.
    Am J Vet Res; 2011 Nov 01; 72(11):1505-13. PubMed ID: 22023129
    [Abstract] [Full Text] [Related]

  • 13. A sensitive and high-throughput LC-MS/MS method for inhibition assay of seven major cytochrome P450s in human liver microsomes using an in vitro cocktail of probe substrates.
    Liu LY, Han YL, Zhu JH, Yu Q, Yang QJ, Lu J, Guo C.
    Biomed Chromatogr; 2015 Mar 01; 29(3):437-44. PubMed ID: 25098274
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. In vitro characterization of 4'-(p-toluenesulfonylamide)-4-hydroxychalcone using human liver microsomes and recombinant cytochrome P450s.
    Lee B, Wu Z, Lee T, Tan XF, Park KH, Liu KH.
    Xenobiotica; 2016 Mar 01; 46(4):350-6. PubMed ID: 26330107
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Strategies for Determining Correct Cytochrome P450 Contributions in Hepatic Clearance Predictions: In Vitro-In Vivo Extrapolation as Modelling Approach and Tramadol as Proof-of Concept Compound.
    T'jollyn H, Snoeys J, Van Bocxlaer J, De Bock L, Annaert P, Van Peer A, Allegaert K, Mannens G, Vermeulen A, Boussery K.
    Eur J Drug Metab Pharmacokinet; 2017 Jun 01; 42(3):537-543. PubMed ID: 27317395
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.